Genzyme Buys Two Stem Cell Therapies | November 10, 2008 Issue - Vol. 86 Issue 45 | Chemical & Engineering News
Volume 86 Issue 45 | p. 25 | Concentrates
Issue Date: November 10, 2008

Genzyme Buys Two Stem Cell Therapies

Department: Business

In a deal worth up to $1.3 billion, Osiris Therapeutics has licensed its lead adult stem cell treatments to Genzyme. Osiris granted Genzyme rights to Prochymal, a preparation of cells isolated from healthy bone marrow that is in Phase III trials for treating graft-versus-host disease and Crohn’s disease, and to Chondrogen, which is in a late-stage trial for treating osteoarthritis. In exchange Osiris snares a $130 million upfront payment and could reap hefty milestones and royalties.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment